Deutsche Bank Ag leans into AI platforms and defensive pharma in 2026-Q1

The biggest dollar adds read like a deliberate re-anchoring around durable cash-flow compounding rather than momentum-chasing. AstraZeneca arrives as a fresh $2.39B stake at 0.79% of the book, instantly a core line in the pharma sleeve and a clear signal that oncology and specialty medicine are now central to their long-term growth stack.

On the tech side, Deutsche Bank is not backing away from AI; it is upgrading its expression. Microsoft, Meta and Amazon all saw meaningful adds, with Meta up 12.5% by shares and Amazon up 5.5%, reinforcing a preference for scale platforms that can monetize AI through cloud, ads and commerce rather than a single exposure point. Broadcom, Micron and Intel adds further emphasize the back-end infrastructure thesis — networking, HBM and CPUs are where they see incremental risk/reward, not simply in adding more NVIDIA.

Outside tech and pharma, three conviction areas stand out:

• XOM: a 16.8% share increase builds Exxon Mobil into a larger anchor in integrated oil, signaling confidence that elevated commodity cash flows can offset tech volatility.
• DB and UBS: the bank doubles down on its own stock (DB up 23.1% by shares) and boosts UBS, preferring restructuring-led European banks over more fully-valued U.S. peers.
• ABT and AMT: Abbott (+21.7% by shares) and American Tower (+12.4%) are classic mean-reversion bets — high-quality franchises currently trading below the fund’s average cost, where they appear comfortable averaging down.

The sell tape is not a factor capitulation; it is a harvesting and redeployment exercise out of crowded, fully-valued winners. Alphabet takes the biggest dollar hit: GOOGL is cut 7.6% by shares, and GOOG another 2.5%, unlocking over $0.8B combined to recycle into Microsoft, Meta and Amazon. The message is not “no more AI,” but “less single-name concentration in one ad-driven model.”

In financials, the rotation is even clearer. JPMorgan is trimmed 18.4% by shares and Bank of America modestly, while Deutsche Bank itself and UBS are both increased. That combination reads as a valuation and regulatory arbitrage: harvest gains in best-of-breed U.S. money-center banks trading rich to book and pivot toward European peers still in self-help mode.

The fund also bleeds risk out of several crowded or defensive corners that have run hard. Eli Lilly is trimmed 6.8%, locking in very large gains to fund the new AstraZeneca position and other healthcare adds. Walmart, Costco and Procter & Gamble changes show a tilt away from the most expensive staples/retail defensives (Walmart and Costco cut) toward more balanced consumer exposure, with PG actually increased.

Elsewhere, small but telling risk reductions in AMD, Linde, Enbridge, Williams and Welltower show a consistent pattern: exit on strength where they are deeply in the green, and shift that capital toward areas where fundamental momentum is intact but sentiment has cooled — like towers, medtech, and underappreciated energy majors.

Despite the noise in individual names, sector rotation is slow and intentional rather than violent. Technology inches down from 51.41% to 50.17%, but that mask conceals a notable internal shift: away from a narrow bet on mega-cap consumer internet and toward a mosaic of platforms (Microsoft, Meta, Amazon) plus plumbing (Broadcom, Micron, Intel, Applied Materials).

Health Care is the clear winner of the quarter, rising to 11.04% from 9.49%. AstraZeneca’s arrival, combined with adds to Johnson & Johnson, Medtronic and Abbott, reflect a view that large-cap pharma and medtech now offer growth at a more reasonable multiple than the red-hot GLP-1 complex, where Eli Lilly is being tactically trimmed. This is classic barbell behaviour: keep a winner (LLY) but spread the bet across diversified drug pipelines and devices.

Energy edges up to 7.11% from 6.9% as they move out of midstream names like Enbridge and into integrated producers and services — Exxon, Chevron and TotalEnergies all see increased stakes, while Schlumberger is modestly trimmed. Finance and Real Estate both drift slightly lower, but the internal rotations matter more than the headline weights: within Finance, U.S. money-center banks are being swapped for European restructuring stories, while within Real Estate, the portfolio leans further into digital infrastructure (Equinix, American Tower) and trims more rate-sensitive healthcare REIT exposure (Welltower).

Taken together, the quarter’s moves sketch a manager preparing for an AI-driven world where returns are more evenly shared across the stack — from chips and cloud to software and telecom — and where multiples in the obvious winners may already be stretched. The book still lives and dies by technology, but it is now hedged by a serious, growing allocation to healthcare and energy cash flow.

The adds in Microsoft, Meta, Amazon, Broadcom, Micron and Intel suggest they still see positive earnings revisions across the AI value chain, just not in a single ticker. At the same time, new and larger positions in AstraZeneca, Johnson & Johnson, Medtronic and Abbott indicate a desire to own secular health demand that is uncorrelated with the chip cycle, while trims in Eli Lilly show discipline in a hype-saturated corner of biotech.

Energy and European banks look like the funding anchors of this strategy. More Exxon, Chevron, TotalEnergies and Deutsche Bank create ballast: high free cash flow yields and restructuring upside that can cushion a derating in high-multiple tech. Meanwhile, incremental buys in American Tower, Equinix and Uber hint at a quietly building conviction in digital infrastructure and asset-light platforms as the next leg of growth.

If the AI trade simply matures rather than implodes, this portfolio is positioned to keep compounding through platforms, infrastructure and select pharma. If volatility spikes, the added ballast in defensives and cash-flow engines gives Deutsche Bank room to be a liquidity provider rather than a forced seller.